Luigino Nascimben, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Perioperative Period | 3 | 2019 | 252 | 0.730 |
Why?
|
| Cross Infection | 1 | 2019 | 1422 | 0.350 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2220 | 0.330 |
Why?
|
| Creatine Kinase | 9 | 1997 | 684 | 0.320 |
Why?
|
| Quality Improvement | 2 | 2019 | 3808 | 0.270 |
Why?
|
| Heart Aneurysm | 1 | 2002 | 114 | 0.200 |
Why?
|
| Hospital Rapid Response Team | 1 | 2022 | 54 | 0.190 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2004 | 854 | 0.190 |
Why?
|
| Glycolysis | 1 | 2004 | 836 | 0.180 |
Why?
|
| Mitral Valve | 2 | 2013 | 1465 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2019 | 5885 | 0.160 |
Why?
|
| Cardiac Output, Low | 2 | 1996 | 191 | 0.160 |
Why?
|
| Airway Management | 1 | 2022 | 312 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2013 | 1086 | 0.150 |
Why?
|
| Myocardium | 7 | 1996 | 4746 | 0.140 |
Why?
|
| Reminder Systems | 1 | 2019 | 386 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 356 | 0.130 |
Why?
|
| Feedback | 1 | 2019 | 790 | 0.130 |
Why?
|
| Enalapril | 1 | 1995 | 310 | 0.110 |
Why?
|
| Kyphoplasty | 1 | 2013 | 44 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2002 | 1959 | 0.100 |
Why?
|
| Polymethyl Methacrylate | 1 | 2013 | 131 | 0.100 |
Why?
|
| Coronary Artery Bypass | 2 | 2013 | 2193 | 0.100 |
Why?
|
| Fractures, Compression | 1 | 2013 | 131 | 0.090 |
Why?
|
| Bone Cements | 1 | 2013 | 325 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2013 | 1400 | 0.090 |
Why?
|
| Mandibular Diseases | 1 | 2010 | 117 | 0.080 |
Why?
|
| Anesthesiology | 1 | 2019 | 1122 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2014 | 1664 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2022 | 3239 | 0.080 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2009 | 202 | 0.080 |
Why?
|
| Intubation, Intratracheal | 2 | 2022 | 1331 | 0.080 |
Why?
|
| Osteonecrosis | 1 | 2010 | 228 | 0.080 |
Why?
|
| Heart Ventricles | 5 | 2013 | 3813 | 0.070 |
Why?
|
| Cardiomegaly | 2 | 2004 | 590 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 1530 | 0.060 |
Why?
|
| Phosphofructokinases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2004 | 14 | 0.060 |
Why?
|
| Aortitis | 1 | 2005 | 76 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 1725 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 865 | 0.060 |
Why?
|
| Troponin I | 1 | 2009 | 652 | 0.060 |
Why?
|
| Laryngoscopy | 1 | 2010 | 707 | 0.060 |
Why?
|
| Hypertension, Renovascular | 3 | 1989 | 115 | 0.060 |
Why?
|
| Heart Failure | 3 | 2013 | 11701 | 0.060 |
Why?
|
| Mitral Valve Prolapse | 1 | 2006 | 212 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2004 | 410 | 0.050 |
Why?
|
| Isoenzymes | 4 | 1996 | 1682 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2014 | 1923 | 0.050 |
Why?
|
| DNA Replication | 1 | 2010 | 1415 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 1997 | 3770 | 0.050 |
Why?
|
| Rats, Wistar | 2 | 2004 | 1848 | 0.050 |
Why?
|
| Myocardial Contraction | 3 | 1996 | 1516 | 0.050 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2022 | 69 | 0.050 |
Why?
|
| Prospective Payment System | 1 | 2022 | 135 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 665 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2004 | 597 | 0.050 |
Why?
|
| Aortic Aneurysm | 1 | 2005 | 648 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15637 | 0.050 |
Why?
|
| Mesocricetus | 3 | 1996 | 252 | 0.050 |
Why?
|
| Energy Metabolism | 3 | 1996 | 2877 | 0.040 |
Why?
|
| Personnel, Hospital | 1 | 2022 | 285 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 2571 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 1867 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 3627 | 0.040 |
Why?
|
| Xenon Isotopes | 1 | 1997 | 67 | 0.040 |
Why?
|
| Cricetinae | 3 | 1996 | 2412 | 0.030 |
Why?
|
| Xenon Radioisotopes | 1 | 1996 | 33 | 0.030 |
Why?
|
| Myosins | 2 | 1989 | 404 | 0.030 |
Why?
|
| Mitochondria | 1 | 2010 | 3620 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 1997 | 144 | 0.030 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11476 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 1997 | 422 | 0.030 |
Why?
|
| Electrocardiography | 3 | 2009 | 6387 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 7407 | 0.030 |
Why?
|
| Blood | 1 | 1997 | 596 | 0.030 |
Why?
|
| Rats | 6 | 2004 | 23704 | 0.030 |
Why?
|
| Hospitalization | 1 | 2013 | 10707 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 1993 | 261 | 0.030 |
Why?
|
| Glucose | 1 | 2004 | 4342 | 0.030 |
Why?
|
| Reference Values | 2 | 1996 | 4921 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1996 | 2263 | 0.030 |
Why?
|
| Captopril | 2 | 1989 | 262 | 0.030 |
Why?
|
| Texas | 1 | 2013 | 403 | 0.030 |
Why?
|
| Humans | 17 | 2022 | 761208 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2013 | 190 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 18220 | 0.020 |
Why?
|
| Kinetics | 2 | 1996 | 6312 | 0.020 |
Why?
|
| Systole | 1 | 2013 | 936 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1920 | 0.020 |
Why?
|
| Mouthwashes | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1996 | 832 | 0.020 |
Why?
|
| Organ Size | 1 | 1995 | 2253 | 0.020 |
Why?
|
| Chest Tubes | 1 | 2010 | 152 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2009 | 113 | 0.020 |
Why?
|
| Turkeys | 3 | 1996 | 44 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2013 | 612 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2010 | 247 | 0.020 |
Why?
|
| Angiography | 1 | 2013 | 1597 | 0.020 |
Why?
|
| Aged | 9 | 2013 | 169288 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1996 | 2335 | 0.020 |
Why?
|
| Male | 13 | 2013 | 360693 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 795 | 0.020 |
Why?
|
| Animals | 10 | 2004 | 168079 | 0.020 |
Why?
|
| Adenosine Triphosphate | 3 | 1997 | 1988 | 0.020 |
Why?
|
| Female | 10 | 2013 | 392544 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 1336 | 0.010 |
Why?
|
| Body Weight | 1 | 1995 | 4618 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 1996 | 2021 | 0.010 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 2087 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 1876 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2010 | 2916 | 0.010 |
Why?
|
| Middle Aged | 7 | 2013 | 220853 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 1056 | 0.010 |
Why?
|
| Hospitals | 1 | 2014 | 3881 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2013 | 10088 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9327 | 0.010 |
Why?
|
| Adult | 4 | 2010 | 221119 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2010 | 3549 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2010 | 1741 | 0.010 |
Why?
|
| Time Factors | 3 | 2010 | 39957 | 0.010 |
Why?
|
| Radiography | 1 | 2010 | 6974 | 0.010 |
Why?
|
| Wound Healing | 1 | 2010 | 2800 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 12474 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 39126 | 0.010 |
Why?
|
| Antimetabolites | 1 | 1997 | 129 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1997 | 333 | 0.010 |
Why?
|
| Furazolidone | 1 | 1996 | 6 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 1997 | 210 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1997 | 319 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1989 | 1728 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 1997 | 438 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2013 | 54435 | 0.010 |
Why?
|
| Propionates | 1 | 1996 | 181 | 0.010 |
Why?
|
| Guanidines | 1 | 1996 | 194 | 0.010 |
Why?
|
| Length of Stay | 1 | 2009 | 6417 | 0.010 |
Why?
|
| Diastole | 1 | 1997 | 782 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2013 | 64681 | 0.010 |
Why?
|
| Creatine | 1 | 1996 | 427 | 0.010 |
Why?
|
| United States | 1 | 2022 | 72339 | 0.010 |
Why?
|
| Iodoacetamide | 1 | 1993 | 33 | 0.010 |
Why?
|
| Heparin | 1 | 1981 | 1632 | 0.010 |
Why?
|
| Phosphorus | 1 | 1993 | 332 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 12728 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 3818 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1997 | 1525 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 12099 | 0.010 |
Why?
|
| Phosphates | 1 | 1993 | 763 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20588 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1996 | 1769 | 0.000 |
Why?
|
| Adolescent | 1 | 1996 | 88298 | 0.000 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1987 | 122 | 0.000 |
Why?
|
| Hypertension | 1 | 1987 | 8536 | 0.000 |
Why?
|
| Peptide Mapping | 1 | 1987 | 259 | 0.000 |
Why?
|
| Risk Factors | 1 | 2013 | 74239 | 0.000 |
Why?
|
| Oxygen | 1 | 1997 | 4227 | 0.000 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1989 | 1331 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 2392 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 59221 | 0.000 |
Why?
|
| Heart | 1 | 1996 | 4431 | 0.000 |
Why?
|
| Calcium | 1 | 1996 | 5719 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 8164 | 0.000 |
Why?
|
| Nitro Compounds | 1 | 1981 | 73 | 0.000 |
Why?
|
| Digoxin | 1 | 1981 | 246 | 0.000 |
Why?
|
| Age Factors | 1 | 1996 | 18384 | 0.000 |
Why?
|
| Diuretics | 1 | 1981 | 611 | 0.000 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1981 | 411 | 0.000 |
Why?
|
| Models, Biological | 1 | 1993 | 9457 | 0.000 |
Why?
|
| Brain | 1 | 1996 | 27092 | 0.000 |
Why?
|
| Aspirin | 1 | 1981 | 3129 | 0.000 |
Why?
|